EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events

Kardiovaskuläres Nebenwirkungs-Meldungsprofil von Tirzepatid: pharmakovigilanzbasierte Analyse von Herzinsuffizienz, Arrhythmien und ischämischen Ereignissen

Daqiu Chen, Zixun Wang, Zhanxiong Xie, Yixing Chen, Shunxiang Luo, Shanghua Xu

Frontiers in Pharmacology · 23.03.2026 · 17

DOI: 10.3389/fphar.2026.1785129 ↗

Auf einen Blick

In FAERS zeigte Tirzepatid in HCP-Meldungen eine niedrigere Meldungswahrscheinlichkeit für Herzinsuffizienz. Für Vorhofflimmern, Tachykardie und ischämische Ereignisse ergab sich kein Signal.

Fragestellung

Wie ist das kardiovaskuläre Nebenwirkungs-Meldungsprofil von Tirzepatid in FAERS zu Herzinsuffizienz, Arrhythmien und ischämischen Ereignissen?

Methode

Retrospektive Pharmakovigilanzstudie mit FAERS von Q2/2022 bis Q3/2025; Disproportionalitätsanalyse mit ROR und Full-Database-Vergleich; Hauptanalyse in HCP-Meldungen.

Ergebnisse

103.693 Tirzepatid-Meldungen. In HCP-Meldungen niedrigere Meldungswahrscheinlichkeit für Herzinsuffizienz: ROR 0,18 (95 %-KI 0,07–0,43). Kein Signal für akuten Myokardinfarkt, Vorhofflimmern oder Tachykardie.

Einschränkungen

92,3 % der Meldungen stammten von Verbrauchern; Gewicht war nur in 5.881 Meldungen dokumentiert; Tachykardie-Signal nur in gewichtsstratifizierten Gesamtanalysen, nicht in HCP-Daten.

Schlussfolgerung der Autor:innen

Tirzepatid zeigte in dieser FAERS-Analyse eine deutlich geringere Meldung von Herzinsuffizienz. Nach Berücksichtigung des Reporter-Bias fanden sich keine Meldungssignale für Vorhofflimmern, Tachykardie oder ischämische Ereignisse.

Kernaussagen

  • 103.693 Tirzepatid-Meldungen in FAERS
  • Herzinsuffizienz in HCP-Meldungen: ROR 0,18 (95 %-KI 0,07–0,43)
  • Kein Signal für Vorhofflimmern, Tachykardie oder ischämische Ereignisse

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.03.2026. Verfasst von Daqiu Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian Province, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is highly effective for glycaemic control and weight reduction. However, its real-world cardiovascular adverse event reporting profile remains incompletely characterised.

Methods

We conducted a retrospective pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) from the second quarter of 2022 (FDA approval of tirzepatide) through the third quarter of 2025. Disproportionality analysis was performed using the Reporting Odds Ratio (ROR) with a concurrent full-database comparator (all other drugs reported in the same quarterly files). Because consumers submitted 92.3% of reports, primary inference was drawn from analyses restricted to healthcare professional (HCP) reports (physicians and pharmacists). Subgroup analyses stratified by age, sex, and body weight were conducted; weight-stratified analyses were confined to reports with documented body weight.

Results

A total of 103,693 unique tirzepatide reports were identified. Consumers accounted for 92.3% of submissions; body weight was documented in 5,881 reports (5.7%). In HCP-restricted analyses, tirzepatide was associated with persistently lower reporting odds for heart failure (ROR 0.18 [95% CI 0.07–0.43]). Similarly, no disproportionate reporting was detected for acute myocardial infarction (ROR 0.45 [0.19–1.08]), while remarkably, zero cases of angina or myocardial ischemia were reported in the HCP cohort. In contrast, no association was detected for atrial fibrillation (ROR 1.02 [0.58–1.80]) or tachycardia (ROR 1.01 [0.68–1.51]) in HCP reports. In weight-stratified analyses (full dataset, restricted to reports with documented weight), elevated RORs for tachycardia were observed in both weight groups (<95 kg: 1.91 [1.54–2.37]; ≥95 kg: 1.57 [1.20–2.05]); however, this finding was not replicated in the HCP-restricted analysis and should be interpreted with caution.

Conclusion

In this real-world FAERS analysis using a concurrent full-database comparator and pre-specified stratification by reporter type, tirzepatide showed disproportionately low reporting of heart failure that was robust in HCP reports and across all subgroups. No reporting signal for atrial fibrillation, tachycardia, or ischemic events was detected after accounting for reporter bias. These findings provide pharmacovigilance evidence that complements the safety database of tirzepatide and generate hypotheses for ongoing cardiovascular outcome trials.

Schlagwörter

Stichwörter der Autor:innen

FAERScardiovascular safetyheart failurepharmacovigilancetirzepatide

Autor:innen und Institutionen

  • Department of Cardiology, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian Province, China.
  • The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecula…

Förderung

  • Natural Science Foundation of Fujian Province

Zitieren

APA

Chen, D., Wang, Z., Xie, Z., Chen, Y., Luo, S., & Xu, S. (2026). Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1785129

Vancouver

Chen D, Wang Z, Xie Z, Chen Y, Luo S, Xu S. Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1785129

BibTeX
@article{Chen2026,
  author = {Chen, Daqiu and Wang, Zixun and Xie, Zhanxiong and Chen, Yixing and Luo, Shunxiang and Xu, Shanghua},
  title = {Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1785129}
}
Kostenlos starten →